![]() |
|
|
Vol. 296, Issue 1, 198-206, January 2001
Department of Pharmacology, Potchefstroom University for CHE,
Potchefstroom, South Africa (T.C.G.); and Department of Pharmacology,
The University of Michigan, Ann Arbor, Michigan (T.C.G., D.E.M.,
P.F.H.)
Naturally occurring isothiocyanates, such as benzyl isothiocyanate
(BITC), are potent and selective inhibitors of carcinogenesis induced
by a variety of chemical carcinogens. These effects appear to be
mediated through favorable modification of both phase I and II enzymes
involved in carcinogen metabolism. The inactivation of rat and human
cytochromes P450 (P450s) in microsomes and the reconstituted system by
BITC was investigated. BITC is a mechanism-based inactivator of rat
P450s 1A1, 1A2, 2B1, and 2E1, as well as human P450s 2B6 and 2D6. BITC
was most effective in inactivating P450s 2B1, 2B6, 1A1, and 2E1,
whereas the activities of human P450 2C9 and rat P450 3A2 were not
altered. The concentrations required for half-maximal inactivation
(KI) of P450s 1A1, 1A2, 2B1, and 2E1 were
35, 28, 16, and 18 µM, respectively. The corresponding values for
kinact were 0.26, 0.09, 0.18, and 0.05 min
1, respectively. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis of P450 2B1 inactivated by [14C]BITC
indicated specific and covalent modification of the P450 apoprotein by
a metabolite of BITC. High-performance liquid chromatography analysis
of the BITC metabolites revealed that benzylamine was the major
metabolite and there were lesser amounts of benzoic acid, benzaldehyde,
N,N'-di-benzylurea, and
N,N'-di-benzylthiourea. Presumably, BITC
was metabolized to the reactive benzyl isocyanate intermediate that
covalently modified the P450 apoprotein or hydrolyzed to form
benzylamine. BITC was an efficient inactivator of P450 2B1 with a
partition ratio of approximately 11:1. This irreversible inactivation of P450s by BITC could contribute significantly to its
chemopreventative action.
This article has been cited by other articles:
![]() |
R. D. Finn, L. A. McLaughlin, S. Ronseaux, I. Rosewell, J. B. Houston, C. J. Henderson, and C. R. Wolf Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5 J. Biol. Chem., November 14, 2008; 283(46): 31385 - 31393. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. von Weymarn, J. A. Chun, and P. F. Hollenberg Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers Carcinogenesis, April 1, 2006; 27(4): 782 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Kent, M. Aviram, M. Rosenblat, and P. F. Hollenberg The Licorice Root Derived Isoflavan Glabridin Inhibits the Activities of Human Cytochrome P450S 3A4, 2B6, and 2C9 Drug Metab. Dispos., June 1, 2002; 30(6): 709 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakajima, R. Yoshida, N. Shimada, H. Yamazaki, and T. Yokoi Inhibition and Inactivation of Human Cytochrome P450 Isoforms by Phenethyl Isothiocyanate Drug Metab. Dispos., August 1, 2001; 29(8): 1110 - 1113. [Abstract] [Full Text] [PDF] |
||||